12:44 IST
NSE
Product Launch
Wanbury Product Launch
Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.
Wanbury Ltd
Wanbury Ltd news stories on ALFA NewsRead the news →- Share price
- ₹198.70
- Market cap
- ₹694.8 Cr
- Revenue (annual)
- ₹650.3 Cr
- Net profit (annual)
- ₹66.13 Cr
- P/E (TTM)
- 12.4×Sector 47.3×
- Promoter holding
- 43.02%+0.00% QoQ
- FII holding
- 0.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Business Update 4Board Meeting Date 4Management Change 3Financial Results 3Annual General Meeting 3Share Pledge 2Results Update 2Product Launch 2Debt & Borrowing 2Price Movement Clarification 1Other Announcement 1Merger & Restructuring 1Legal & Regulatory 1Employee Stock Options 1Earnings Call 1
Time
2 announcements with these filters
13:31 IST
BSE
Product Launch
Wanbury Product Launch
Wanbury Limited launched new APIs globally through regulatory submissions in Singapore, Malaysia, and Korea. The Patalganga facility also received zero observations from Korea's MFDS.